布申Yinao药丸通过调节PI3K/Akt通路和肠道微生物群来改善阿尔茨海默病老鼠的认知功能
Shunfeng Lan1, Fan Gao1, Rong Ji1
1Key Laboratory of Basic and Application Research of Beiyao (Ministry of Education), Heilongjiang University of Chinese Medicine, Harbin 150040, People's Republic of China.
Fitoterapia
|November 19, 2025
概括
在阿尔茨海默病 (AD) 鼠群中,Bushen Yinao Pill (BSYN) 显著改善了认知功能,并减少了大脑损伤. 这种传统中医药也对肠道微生物群和关键细胞通路产生了积极影响,为阿尔茨海默病治疗提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 传统中国医药 传统中国医药
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是认知能力下降.
- 传统中医药 (TCM),就像布申亚诺药 (BSYN) 一样,用于治疗记忆丧失和功能缺陷.
- 了解AD中BSYN的机制对于开发新型治疗策略至关重要.
研究的目的:
- 为了研究BSYN在阿尔茨海默氏病老鼠模型上的治疗效果.
- 阐明BSYN作用的基本机制,包括其对PI3K/Akt通路和肠道微生物群的影响.
主要方法:
- 阿尔茨海默病的老鼠模型由Aβ1-42,和D-银糖诱导.
- 使用莫里斯水迷宫测试评估认知功能.
- 分析海马病理 (HE染色),氧化应激和胆固醇标记物 (ELISA),PI3K/Akt通路蛋白质 (Western blot) 和肠道微生物群 (16S rDNA测序).
主要成果:
- 在AD大鼠中,BSYN治疗显著改善了认知表现,并减少了海马的损伤.
- BSYN通过增加p-PI3K和p-Akt,并减少GSK-3β来调节PI3K/Akt通路.
- BSYN恢复了肠道微生物的多样性,促进有益的细菌 (Lactobacillus) 和减少有害的属 (Lachnospiraceae NK4A136).
结论:
- 布申Yinao药丸显示出对阿尔茨海默病的显著治疗潜力.
- BSYN通过改善认知功能,减少神经炎症和调节肠道微生物群来发挥其作用.
- 这些发现支持BSYN作为进一步开发神经退行性疾病治疗的有希望的候选人.
相关概念视频
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
523
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
523
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


